JNCI Journal of the National Cancer Institute · 2016 · 77 citations · 37 references
MedicineDermatologyOncologyCutaneous OncologyDermatopathologyTumor PathologyCancer Survival AnalysisMalignant NeoplasmsMelanocytic TumorsSkin Cancer Risk FactorsSkin TumorsTumor ClassificationDe Novo ClassificationMelanoma ClassificationMelanoma HistopathologyNevoid MelanomaSkin Tumor ClassificationSkin Tumor PrognosisTumor Thickness PrognosisTumor Ulceration
BACKGROUND: Although 20% to 30% of melanomas are histopathologically 'nevus associated,' the majority of melanomas arise de novo, ie, in clinically normal skin with no associated nevus. We examined whether these forms of melanoma differed in their associations with clinical and histopathologic features and patient survival. METHODS: We analyzed two prospective cohorts from our institution with protocol-driven follow-up information (NYU1, n = 1024; NYU2, n = 1125). We used univariate and multivariable analyses to examine associations between de novo vs nevus-associated melanoma classification and age, anatomic site, tumor thickness, tumor ulceration, mitotic index, histological subtype, clinical stage, and survival. We tested the associations identified in NYU1 using NYU2 as a replication cohort. All tests of statistical significance were two-sided. RESULTS: In NYU1, de novo melanomas were associated with tumor thickness greater than 1.0 mm (odds ratio [OR] = 1.96, 95% confidence interval [CI] = 1.43 to 2.70, P < .001), ulceration (OR = 1.65, 95% CI = 1.10 to 2.54, P = .02), nodular subtype (OR = 3.26, 95% CI = 1.70 to 7.11, P = .001), greater than stage I (OR = 2.35, 95% CI = 1.65 to 3.40, P < .001), older age (OR = 1.64, 95% CI = 1.18 to 2.30, P = .004), and shorter overall survival (HR = 1.63, 95% CI = 1.22 to 2.18, P < .001). In NYU2, de novo melanoma was again statistically significantly associated with thickness greater than 1.0 mm (OR = 2.24, 95% CI = 1.72 to 2.93, P < .001), ulceration (OR = 2.88, 95% CI = 1.95 to 4.37, P < .001), nodular subtype (OR = 2.41, 95% CI = 1.75 to 3.37, P < .001), greater than stage I (OR = 2.42, 95% CI = 1.80 to 3.29, P < .001), older age (OR = 1.68, 95% CI = 1.31 to 2.17, P < .001), and shorter overall survival (HR = 2.52, 95% CI = 1.78 to 3.56, P < .001). In multivariable analysis, de novo classification was an independent, poor prognostic indicator in NYU2 (HR = 1.70, 95% CI = 1.19 to 2.44, P = .004). Male patients had a statistically significantly worse survival than female patients if their melanoma was de novo (NYU1, P < .001; NYU2, P < .001); unexpectedly, there was no sex difference in survival among patients with nevus-associated tumors. CONCLUSIONS: These data suggest that de novo melanomas are more aggressive than nevus-associated melanomas. This classification scheme may also provide a useful framework for investigations into sex differences in melanoma outcomes.
37
Model Predicting Survival in Stage I Melanoma Based on Tumor Progression
W. H. Clark, David E. Elder, DuPont Guerry et al. · JNCI Journal of the National Cancer Institute · 1989 · 1.2K citations
Medicine, Dermatology, Oncology +17
The Genetic Evolution of Melanoma from Precursor Lesions
A. Hunter Shain, Iwei Yeh, Ivanka Kovalyshyn et al. · New England Journal of Medicine · 2015 · 1.1K citations · Full text
Sex Disparities in Cancer Mortality and Survival
Michael B. Cook, Katherine A. McGlynn, Susan S. Devesa et al. · Cancer Epidemiology Biomarkers & Prevention · 2011 · 533 citations · Full text
Medicine, Biostatistics, Oncology +17